Table 7Summary table for KQ 2—venous thromboembolism

Study CharacteristicNumber of Studies (Patients)
Total number of studies (patients)3 (8541)
Factor Xa inhibitor, dose
Rivaroxaban, 20 mg daily1 (3449)
Direct thrombin inhibitors, dose
Dabigatran, 150 mg twice daily1 (2564)
 Ximelagatran, 36 mg twice daily1 (2528)
Study duration:
 6 months2 (5092)
 12 months1 (3449)
Mean age
 50–60 years3 (8541)
 60–70 years
Sex
 Men3 (4763)
 Women3 (3714)
DVT/PE etiologya
Idiopathic/unprovoked1 (2138), 2 NR
 Active cancer3 (655)
 Prior VTE3 (1855)
Adjusted-dose warfarin range
 Time above range (%)2 (16.2–19%), 1 NR
 Time in range (%)3 (57.7–61%)
 Time below range (%)2 (19–21%), 1 NR
a

Some subjects may have had more than one risk factor.

Abbreviations: DVT = deep venous thrombosis; NR = not reported; PE = pulmonary embolism; VTE = venous thromboembolism

From: RESULTS

Cover of Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism
Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism [Internet].
Adam SS, McDuffie JR, Ortel TL, et al.
Washington (DC): Department of Veterans Affairs (US); 2012 Apr.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.